

1 **Type 1 and type 2 diabetes mellitus: Clinical outcomes due to COVID-19.**

2 **Protocol of a systematic literature review.**

3 **Type 1 and type 2 diabetes in COVID-19. Systematic review protocol**

4 Juan Pablo Pérez Bedoya^{1¶,#a}, Alejandro Mejía Muñoz^{2¶}, Noël Christopher
5 Barengo^{3&}, Paula Andrea Diaz Valencia^{1&}.

6 ¹ Epidemiology Group. National Faculty of Public Health, University of Antioquia,
7 Medellín, Colombia.

8 ² Biology and control of infectious diseases group. Faculty of exact and natural
9 sciences, University of Antioquia, Medellín, Colombia.

10 ³ Associate professor. Department of Translational Medicine, Herbert Wertheim
11 College of Medicine & Department of Global Health, Robert Stempel College of
12 Public Health and Social Work, Florida International University, Miami, FL, USA.

13 #a Current Address: University of Antioquia. National Faculty of Public Health:
14 Street. 62 #52-59, Medellin, Antioquia.

15

16 * Corresponding author

17 E-mail: juan.perez42@udea.edu.co (JPPB)

18

19 ¶ These authors contributed equally to this work

20 & These authors also contributed equally this work

21 **Abstract**

22 **Introduction**

23 Diabetes has been associated with an increased risk of complications in patients
24 with COVID-19. Most studies do not differentiate between patients with type 1 and
25 type 2 diabetes, which correspond to two pathophysiological distinct diseases that
26 could represent different degrees of clinical compromise.

27 **Objective**

28 To identify if there are differences in the clinical outcomes of patients with COVID-
29 19 and diabetes (type 1 and type 2) compared to patients with COVID-19 without
30 diabetes.

31 **Methods**

32 Observational studies of patients with COVID-19 and diabetes (both type 1 and
33 type 2) will be included without restriction of geographic region, gender or age,
34 whose outcome is hospitalization, admission to intensive care unit or mortality
35 compared to patients without diabetes. Two authors will independently perform
36 selection, data extraction, and quality assessment, and a third reviewer will resolve
37 discrepancies. The data will be synthesized regarding the sociodemographic and
38 clinical characteristics of patients with diabetes and without diabetes accompanied
39 by the measure of association for the outcomes. The data will be synthesized
40 regarding the sociodemographic and clinical characteristics of patients with

41 diabetes and without diabetes accompanied by the measure of association for the
42 outcomes.

43 **Expected results**

44 Update the evidence regarding the risk of complications in diabetic patients with
45 COVID-19 and in turn synthesize the information available regarding type 1 and
46 type 2 diabetes mellitus, to provide keys to a better understanding of the
47 pathophysiology of diabetics.

48 **Systematic review registry**

49 This study was registered at the International Prospective Registry for Systematic
50 Reviews (PROSPERO) - CRD42021231942.

51

52

53

54

55

56

57 Introduction

58 The Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2), the
59 causal viral agent of coronavirus disease 2019 (COVID-19), currently has the world
60 in one of the greatest public health crises of recent times since its appearance at
61 the end of 2019 in the city of Wuhan, China [1]. The infection has a mild or even
62 asymptomatic course in most cases, but in elderly patients (over 60 years-of-age)
63 and in those with pre-existing chronic comorbidities, it can progress severe
64 complications such as pneumonia, acute respiratory distress (ARDS) with
65 hyperinflammatory involvement and multi-organ failure, leading in some cases to
66 death [2].

67 Different studies have reported that patients diagnosed with diabetes who suffer
68 from COVID-19 disease have higher morbidity and mortality compared with people
69 without diabetes [3]. An analysis by Gude Sampedro et al using prognostic models
70 found that diabetic patients had greater odds of being hospitalized (OR 1.43; 95%
71 CI: 1.18 to 1.73), admitted to the intensive care unit (OR 1.61; 95% CI: 1.12 to
72 2.31) and dying from COVID-19 (OR 1.79; 95% CI %: 1.38 to 2.32) compared with
73 patients without diabetes [4]. However, it is difficult to establish whether diabetes
74 alone directly contributed to the increase likelihood of complications.

75 Several studies using secondary data have emerged during the course of the
76 pandemic that seek to determine the association of diabetes with mortality and
77 other clinical outcomes in patients with COVID-19, such as, for example, a meta-
78 analysis carried out by Shang et al. of severe infection and mortality from COVID-

79 19 in diabetic patients compared with those without diabetes. They reported that
80 patients with COVID-19 and diabetes had higher odds of serious infection (OR =
81 2.38, 95% CI: 2.05 to 2.78) and mortality (OR = 2, 21, 95% CI: 1.83 to 2.66) than
82 patients without diabetes [5]. Despite the fact that there are several primary studies
83 that attempt to explain the association between diabetes and COVID-19, most
84 studies lack epidemiological rigor in the design and methodology used [6]. In
85 addition, many of them did not distinguish between type 1 and type 2 diabetes,
86 which are two very different conditions with different clinical development and
87 pathophysiological mechanisms [7]. This may lead to different degrees of clinical
88 complications from COVID-19. Currently, there is a gap in knowledge about the
89 complications in patients with COVID-19 according to the type of diabetes.
90 Moreover, only limited information exist how COVID-19 affects type 1 patients
91 [8,9].

92 The objective of this systematic literature review will be to identify whether there
93 are differences in the clinical outcomes of both type 1 and type 2 diabetes patients
94 diagnosed with COVID-19 compared with patients with COVID-19 without a
95 diagnosis of diabetes. This study will provide scientific evidence regarding the risk
96 of complications in diabetic patients with COVID-19 and, in turn, synthesize the
97 available information regarding to type 1 and type 2 diabetes.

98 **Methods/Design**

99 **Study design**

100 This systematic literature review protocol was prepared according to the Preferred
101 Reporting Elements for Systematic Review and Meta-Analysis Protocols (PRISMA-
102 P) [10] (S1 Appendix). The results of the final systematic review will be reported
103 according to the preferred reporting items for systematic reviews and meta-
104 analyses (PRISMA 2020) [11,12]. In the event of significant deviations from this
105 protocol, they will be reported and published with the results of the review.

106 **Eligibility Criteria**

107 **Participants (population)**

108 Patients with a confirmed diagnosis of COVID-19 without restriction of geographic
109 region, gender or age of the participants, in which the diagnostic algorithm used to
110 confirm SARS-CoV-2 infection is adequately presented, as it is the case of
111 standardized molecular biology laboratory methods such as RT-PCR (real-time
112 reverse transcriptase polymerase chain reaction) and/or antigen test for the
113 detection of virus surface proteins, or failing that, diagnosis clinical or
114 epidemiological based on international guidelines and recommendations by the
115 WHO or/and the Center for Disease Control and Prevention (CDC).

116 **Exposure**

117 Patients with COVID-19 and concomitant diagnosis of unspecified diabetes
118 mellitus, differentiated into type 1 diabetes mellitus or type 2 diabetes mellitus,
119 without restriction of geographic region, gender, or age of the patients, who present

120 definition of clinical criteria and /or paraclinical tests used by researchers to classify
121 patients according to their diabetes status.

122 **Comparator**

123 Patients with COVID-19 who do not have a concomitant diagnosis of diabetes
124 mellitus.

125 **Outcome**

126 The main endpoint is all-cause mortality (according to the definitions of each
127 primary study) and the secondary outcomes are hospitalization and admission to
128 the ICU, where the authors specify a clear definition based on clinical practice
129 guidelines and provide a well-defined criteria for patient outcomes.

130 **Type of study**

131 Primary observational original research studies (prospective or retrospective
132 cohort, case-control design, and cross-sectional studies) will be included in this
133 systematic review.

134 **Exclusion criteria**

135 Clinical trials, editorials, letters to the editor, reviews, case reports, case series,
136 narrative reviews or systematic reviews and meta-analyses, as well as research in
137 the field of basic sciences based on experimental laboratory models, will be
138 excluded. Similarly, original research articles that only include other types of
139 diabetes such as monogenic diabetes, gestational diabetes, latent autoimmune

140 diabetes in adults, ketosis-prone diabetes, among others, or articles with a
141 publication status prior to review will be excluded.

142 **Information sources and search strategy**

143 For the preparation of the search strategy, the recommendations of the PRISMA-S
144 guide [13] will be adopted. Relevant articles will be identified by electronic search
145 applying the equation previously developed by the researchers and validated by an
146 expert librarian (S2 Appendix). The following electronic bibliographic databases will
147 be used: MEDLINE, EMBASE, LILACS, OVID MEDLINE and WHO (COVID-19
148 Global literature on coronavirus disease) with a publication date from December
149 2019 to March 20, 2022, without language restriction. To identify other potentially
150 eligible studies, the references of relevant publications will be reviewed to perform
151 a snowball manual search.

152 **Study selection process**

153 Two investigators will independently assess all the titles and abstracts of the
154 retrieved articles using the free access Rayyan software® [14]. Disagreement will
155 be resolved in the first instance through discussion and in a second instance
156 through a third reviewer. Articles that meet the eligibility criteria will be included.
157 The full text will be read independently by two researchers. Discrepancies will be
158 resolved through discussion or a third reviewer. The process of identification,
159 screening and inclusion of primary studies will be described and presented using
160 the flow chart recommended by the PRISMA statement in its latest version 2020
161 [11,12].

162 **Data collection and extraction**

163 Standardized and validated forms will be used to collect the data extracted from
164 the primary studies, accompanied by a detailed instruction manual to specify the
165 guiding questions, and avoid the introduction of bias. This process will be carried
166 out by two researchers independently. A third investigator will verify the extracted
167 data to ensure the accuracy of the records. The authors of the primary studies will
168 be contacted to resolve any questions that may arise. The reviewers will resolve
169 disagreements through discussion and one of the two referees will adjudicate the
170 discrepancies presented through discussion and consensus.

171 In specific terms, the following data will be collected both for the primary studies
172 that report diabetes and COVID-19 and for those that differentiate between DMT1
173 and DMT2: author, year and country where the study was carried out; study
174 design; general characteristics of the population, sample size, demographic data of
175 the participants (sex, age, ethnicity), percentage of patients with diabetes,
176 percentage of patients with type 1 and/or type 2 diabetes, percentage of patients
177 without diabetes, frequency of comorbidities in diabetics and non-diabetics,
178 percentage of diabetic and non-diabetic patients who presented the outcomes
179 (hospitalization, ICU admission and mortality) and association measures reported
180 for the outcomes. Data extraction will be done using a Microsoft Excel 365 ®
181 spreadsheets.

182 **Quality evaluation**

183 The study quality assessment tool provided by the National Institutes of Health
184 (NIH) [15] will be used for observational studies such as cohort, case-control, and
185 cross-sectional. Two tools will be used: one for cohort and cross-sectional studies
186 (14 questions/domains) and one for case-control studies (12 questions/domains).
187 These tools are aimed at detecting elements that allow evaluation of possible
188 methodological problems, including sources of bias (for example, patient selection,
189 performance, attrition and detection), confounding, study power, the strength of
190 causality in the association between interventions and outcomes, among other
191 factors. The different tools that will be used reflect a score of "1" or "0" depending
192 on the answer "yes" or "no", respectively for each question or domain evaluated, or
193 failing that, the indeterminate criterion option. For observational cohort studies,
194 which consist of 14 risk of bias assessment domains, the studies will be classified
195 as having good quality if they obtain ≥ 10 points, of fair quality if they obtain 8 to 9
196 points, and of poor quality if they obtain less than 8 points. On the other hand, in
197 the case of case-control studies that consist of 12 bias risk assessment domains,
198 the studies will be classified as good quality if they obtained ≥ 8 points, regular
199 quality if they obtained 6 to 7 points and of poor quality if they obtained less than 6
200 points. However, the internal discussion between the research team will always be
201 considered as the primary quality criterion.

202 **Data synthesis**

203 A narrative synthesis with summary tables will be carried out according to the
204 recommendations adapted from the Synthesis Without Meta-analysis (SWiM)
205 guide to describe in a structured way the methods used, and the findings found in

206 the primary studies, as well as the criteria for grouping of the studies [16]. A
207 narrative synthesis will be presented in two sections, one for patients with COVID-
208 19 and diabetes and another for patients with COVID-19 and type 1 or type 2
209 diabetes.

210 Assessment of clinical and methodological heterogeneity will determine the
211 feasibility of the meta-analysis. Possible sources of heterogeneity identified are the
212 clinical characteristics of the study population, the criteria used to define the
213 outcomes in the groups of patients, the time period of the pandemic in which the
214 study was carried out, and the availability of measurement and control for potential
215 confounding factors. For this reason, it is established a priori that this diversity of
216 findings will make it difficult to carry out an adequate meta-analysis [17]. However,
217 if meta-analysis is considered feasible, the random effects model will be used due
218 to the high probability of heterogeneity between studies. Statistical heterogeneity
219 will be assessed using the X^2 test and the I^2 statistic, and publication bias
220 assessed using funnel plots if there are sufficient (>10) studies [18].

221 **Exploratory ecological analysis**

222 An exploratory ecological analysis of the association between the frequency of
223 clinical outcomes of diabetic patients with COVID-19 and the indicators related to
224 the health care dimension, reported for the different countries analyzed by means
225 of the correlation coefficient, will be carried out. The open public databases of the
226 World Bank (WB) [19], the World Health Organization (WHO) [20] and Our World
227 In Data [21] will be used to extract population indicators related to health care,

228 among those prioritized, universal health coverage, hospital beds per 1,000
229 people, doctors per 1,000 people, current health spending as a percentage of
230 gross domestic product (GDP), percentage of complete vaccination coverage for
231 COVID-19.

232 **Discussion**

233 Since the first epidemiological and clinical reports were released from the city of
234 Wuhan regarding the clinical characteristics of patients with COVID-19, a high
235 incidence of chronic non-communicable diseases has been observed in Covid-19
236 patients. Current scientific evidence has shown that certain comorbidities increase
237 the risk for hospitalization, severity of illness or death from COVID-19, such as
238 hypertension, cardiovascular disease, chronic kidney disease, chronic respiratory
239 disease, diabetes, among others [22].

240 One of the main chronic comorbidities affected by the COVID-19 pandemic is
241 diabetes. Multivariate analysis of several observational epidemiological studies
242 have revealed that COVID-19 patients with diabetes were at increased risk of
243 hospitalization, ICU admission, and mortality compared with patients without
244 diabetes [4].

245 For this reason, it is expected that this systematic literature review will provide
246 scientific support regarding the outcomes and complications that patients
247 diagnosed with COVID-19 with type 1 or type 2 diabetes present compared with
248 patients without diabetes. This information will be useful for healthcare personnel,
249 public health professionals and epidemiologists involved in patient care or decision

250 making, generating epidemiological evidence. Thus, highlighting the decisive role
251 of epidemiological research in the context of the pandemic, especially in the field of
252 diabetes epidemiology may improve comprehensive management and care of
253 diabetic patients. This study may also provide important information that can be
254 used to update of clinical practice guidelines.

255 **The status of the study**

256 The study is in the selection phase of the records by applying the eligibility criteria
257 to the titles and abstracts. Completion of the project is expected in September
258 2022 with the publication of the results.

259 **Conclusions**

260 This report describes the systematic review protocol that will be utilized to update
261 the evidence regarding the risk of complications in diabetic patients with COVID-19
262 and in turn synthesize the information available regarding DM1 and DM2, to
263 provide keys to a better understanding of the pathophysiology of diabetics.

264 **Acknowledgments**

265 This research was developed within the "Repository for the surveillance of risk
266 factors for chronic diseases in Colombia, the Caribbean and the Americas"
267 framework and financially supported by a grant of Colciencias 844 (grant number
268 111584467754).

269 **References**

- 270 1. Singhal T: A Review of Coronavirus Disease-2019 (COVID-19). Indian J
271 Pediatr. 2020, 87:281-286. doi: 10.1007/s12098-020-03263-6.
- 272 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
273 infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-
274 506. doi: 10.1016/S0140-6736(20)30183-5.
- 275 3. Obukhov AG, Stevens BR, Prasad R, Li Calzi S, Boulton ME, Raizada MK, et
276 al. SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With
277 Increased Morbidity and Mortality in Individuals With Diabetes. Diabetes. 2020,
278 69:1875-1886. doi: 10.2337/dbi20-0019.
- 279 4. Gude-Sampedro F, Fernández-Merino C, Ferreira L, Lado-Baleato Ó,
280 Espasandín-Domínguez J, Hervada X, et al. Development and validation of a
281 prognostic model based on comorbidities to predict COVID-19 severity: a
282 population-based study. Int J Epidemiol. 2021, 50:64-74. doi:
283 10.1093/ije/dyaa209.
- 284 5. Shang L, Shao M, Guo Q, Shi J, Zhao Y, Xiaokereti J, et al. Diabetes Mellitus is
285 Associated with Severe Infection and Mortality in Patients with COVID-19: A
286 Systematic Review and Meta-analysis. Arch Med Res. 2020, 51:700-709. doi:
287 10.1016/j.arcmed.2020.07.005.
- 288 6. Selvin E, Juraschek SP: Diabetes Epidemiology in the COVID-19 Pandemic.
289 Diabetes Care. 2020, 43:1690-1694. doi: 10.2337/dc20-1295.
- 290 7. Gregory JM, Slaughter JC, Duffus SH, Smith TJ, LeSturgeon LM, Jaser SS, et
291 al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective
292 Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes
293 Care. 2021, 44:526-532. doi: 10.2337/dc20-2260.

- 294 8. Vamvini M, Lioutas VA, Middelbeek RJW. Characteristics and Diabetes Control
295 in Adults With Type 1 Diabetes Admitted With COVID-19 Infection. *Diabetes*
296 *Care*. 2020, 43:e120-e122. doi: 10.2337/dc20-1540.
- 297 9. Ebekozi OA, Noor N, Gallagher MP, Alonso GT. Type 1 Diabetes and
298 COVID-19: Preliminary Findings From a Multicenter Surveillance Study in the
299 U.S. *Diabetes Care*. 2020, 43:e83-e85. doi: 10.2337/dc20-1088.
- 300 10. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.
301 Preferred reporting items for systematic review and meta-analysis protocols
302 (PRISMA-P) 2015 statement. *Syst Rev*. 2015, 4:1-9. doi: 10.1186/2046-4053-4-
303 1.
- 304 11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et
305 al. The PRISMA 2020 statement: An updated guideline for reporting systematic
306 reviews. *PLoS Med*. 2021, 18:1-15. doi: 10.1371/journal.pmed.1003583.
- 307 12. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
308 PRISMA 2020 explanation and elaboration: updated guidance and exemplars
309 for reporting systematic reviews. *BMJ*. 2021, 372:1-36. doi: 10.1136/bmj.n160.
- 310 13. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al.
311 PRISMA-S: an extension to the PRISMA Statement for Reporting Literature
312 Searches in Systematic Reviews. *Syst Rev*. 2021, 10:1-19. doi:
313 10.1186/s13643-020-01542-z.
- 314 14. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and
315 mobile app for systematic reviews. *Syst Rev*. 2016, 5:1-10. doi:
316 10.1186/s13643-016-0384-4.

- 317 15. National Institutes of Health (NIH) [Internet]. Study Quality Assessment Tools;
318 2021. [cited 16 June 2022]. Available at: [https://www.nhlbi.nih.gov/health-](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools)
319 [topics/study-quality-assessment-tools](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools).
- 320 16. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et
321 al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting
322 guideline. *BMJ*. 2020, 368:1-6. doi: 10.1136/bmj.l6890.
- 323 17. Cochrane Handbook for Systematic Reviews of Interventions; 2022. [cited 16
324 June 2022]. Available at: <https://training.cochrane.org/handbook/current>.
- 325 18. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing
326 heterogeneity in meta-analysis: Q statistic or I² index?. *Psychol Methods*. 2006,
327 11:193-206. doi: 10.1037/1082-989X.11.2.193.
- 328 19. World Bank Group [Internet]. World Bank Indicators; 2022. [cited 16 June
329 2022]. Available at: <https://datos.bancomundial.org/indicador>.
- 330 20. World Health Organization (WHO) [Internet]. Global Health Observatory Data
331 Repository; 2021. [cited 16 June 2022]. Available at:
332 <https://apps.who.int/gho/data/node.home>.
- 333 21. Our World In Data [Internet]. Statistics and Research Coronavirus Pandemic
334 (COVID-19); 2022. [cited 16 June 2022]. Available at:
335 <https://ourworldindata.org/coronavirus>.
- 336 22. Centers for Disease Control and Prevention [Internet]. COVID-19. People with
337 Certain Medical Conditions; 2021. [cited 16 June 2022]. Available at:
338 [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html?CDC_AA_refVal=ht...)
339 [with-medical-conditions.html?CDC_AA_refVal=ht...](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html?CDC_AA_refVal=ht...)

340 **Supporting information**

341 **S1 Appendix.** PRISMA-P (Preferred Reporting Items for Systematic review and
342 Meta-Analysis Protocols) 2015 checklist: Recommended items to address in a
343 systematic review protocol.

344 **S2 Appendix.** Search string details for each database.